ArticleJapanese journal of ophthalmology2025
Therapeutic outcomes of ranibizumab for zone ii stage 2 retinopathy of prematurity with plus disease.
Yoshihiro Nakagawa et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it